From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.04
First Reported 2008
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 1
Disease Relevance 1.00
Pain Relevance 0.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

embryo development (PDGFA) DNA binding (TXK) cell-cell signaling (PDGFA)
cytoplasm (TXK) extracellular space (PDGFA) extracellular region (PDGFA)
TXK (Homo sapiens)
PDGFA (Homo sapiens)
Pain Link Frequency Relevance Heat
headache 4 50.96 Quite High
antagonist 1 50.24 Quite High
Inflammation 5 5.00 Very Low Very Low Very Low
peripheral neuropathy 2 5.00 Very Low Very Low Very Low
Pain 2 5.00 Very Low Very Low Very Low
tolerance 1 5.00 Very Low Very Low Very Low
Potency 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Breast Cancer 59 98.56 Very High Very High Very High
Lung Cancer 1 94.96 High High
Advanced Or Metastatic Breast Cancer 84 86.80 High High
Lymphatic System Cancer 1 69.52 Quite High
Toxicity 14 53.84 Quite High
Headache 4 50.96 Quite High
Vomiting 13 50.56 Quite High
Diarrhoea 14 50.24 Quite High
Cancer 35 47.84 Quite Low
Disease 22 45.88 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Motesanib is a small molecule tyrosine kinase inhibitor of VEGF that targets VEGFR 1, 2, 3 and PDGF that has been evaluated in preclinical models in combination with either tamoxifen or docetaxel and was shown to have potential use in breast cancer.[68] A large phase II clinical trial is ongoing evaluating motesanib and paclitaxel in the treatment of breast cancer).[47]
molecule tyrosine kinase Positive_regulation (targets) of PDGF associated with breast cancer
1) Confidence 0.04 Published 2008 Journal J Hematol Oncol Section Body Doc Link PMC2579406 Disease Relevance 1.00 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools